DexCom, Inc. (DXCM)
Antes de la apertura del mercado:
DexCom, Inc.
6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 6,300
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kevin Ronald Sayer | Exec. Chairman, CEO & Pres | 2.39M | N/D | 1958 |
| Mr. Jereme M. Sylvain | Exec. VP, CFO & Chief Accounting Officer | 783.16k | N/D | 1980 |
| Mr. Jacob Steven Leach | Exec. VP & COO | 915.93k | N/D | 1978 |
| Mr. Paul R. Flynn | Exec. VP of Global Revenue | 761.52k | N/D | 1969 |
| Mr. Girish Naganathan | Exec. VP of R&D and CTO | N/D | N/D | N/D |
| Mr. Sean Christensen | Director of Corp. Affairs & Head of Investor Relations | N/D | N/D | N/D |
| Mr. Michael Brown | Exec. VP & Chief Legal Officer | N/D | N/D | 1970 |
| Mr. Matthew Dolan | Exec. VP of Strategy, Corp. Devel. & Dexcom Labs | N/D | N/D | 1981 |
| Ms. Sadie M. Stern | Exec. VP & Chief HR Officer | N/D | N/D | 1975 |
| Mr. Andrew K. Balo | Exec. VP of Global Medical Affairs, Access & Evidence | N/D | N/D | 1948 |
Descripción
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de DexCom, Inc. a partir del 1 de febrero de 2023 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 10; Derechos del accionista: 6; Compensación: 6.
